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LETTERS TO THE EDITOR
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1Regarding “Trends in the national outcomes and
costs for claudication and limb threatening ischemia:
Angioplasty vs bypass graft”
I read with much interest the article “Trends in the national
outcomes and costs for claudication and limb threatening isch-
emia: angioplasty versus bypass graft” by Sachs et al, which ap-
peared in the October issue of the Journal. The authors analyzed
the results and costs of angioplasty with or without stenting and
bypass surgery, reviewing the data of the National Registry.1
I was quite surprised to see that, in the USA, there has been an
increasing use of revascularization techniques in patients with
lower limb claudication. More than half of the procedures of lower
limb revascularization from 1999 to 2007 have been performed in
patients with claudication. The number of percutaneous translu-
minal angioplasty (PTA) procedures, with or without stenting,
performed in patients with claudication has been steadily increas-
ing. The number of PTAs for claudication almost doubled in 8
years.
This attitude has been generally based on the objective results
that in-hospital amputation after angioplasty for claudication is
quite low (0.1%) and complications rare. The main dogma in all
centers is that, on the basis of this evidence, in patients who have a
life-interfering claudication, PTA is indicated. Is it not possible
that too often “claudication is judged severe?”
Looking at the data of the National Registry (reporting only
20% of the cases), extrapolation brings one to the conclusion that,
in an 8-year period, almost 1.5 million people had some kind of
revascularization (more often angioplasty) for severe lower limb
claudication. The average age in the patient sample was 67 years,
and, at this age, the prevalence of lower limb claudication is about
10%. If we consider that in the USA the population aged more than
65 years is about 60 million (approximate data), we come to the
conclusion that more than half of the patients had severe claudica-
tion (10% of 60 million is 6 million; so out of 6 million claudicants,
3 million had some kind of revascularization).
Naturally, the data reported in the article are quite approxi-
mate, as well as my extrapolations. But what really worries me is
that the number of PTAs performed for claudication is increasing
rapidly, with a cost of about $20,000 per patient, on the assump-
tion that the procedure “does not harm the patient.”
The natural history of claudication is a benign one, with only
1% to 2% of patients who will suffer severe ischemia in a 5-year
period. The best medical therapy and physical training have a
significant role not only in abolishing, at least partially, the symp-
toms of claudication but also in improving the general physical
status of the patient. More strict guidelines are needed to ensure an
optimal use of PTA in patients with claudication.
Antonio V. Sterpetti, MD, FACS, FRCS
Istituto Pietro Valdoni
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REFERENCE
1. Sachs T, Pomposelli F, Hamdam A, Wyers M, Schermerhorn M.
Trends in the national outcomes and costs for claudication and limb
threatening ischemia: angioplasty vs bypass surgery. J Vasc Surg
2011;54:1021-31.doi:10.1016/j.jvs.2011.11.143egarding “A comparison of covered vs bare
xpandable stents for the treatment of aortoiliac
cclusive disease”
We have read the recent article “A comparison of covered vs bare
xpandable stents for the treatment of aortoiliac occlusive disease” by
wipatay et al.1 We would like to congratulate the authors on their
tudy, which is the first randomized controlled trial to show that
olytetrafluoroethylene (PTFE)-covered stents indeed provide a
igher freedom from restenosis rates compared to bare metal stents.
e do, however, believe that there are some important limitations to
he study, which reduce its applicability for daily practice.
The authors have chosen to include all patients with common
liac artery (CIA) and external iliac artery (EIA) atherosclerotic lesions.
lthough this is in fact common practice in virtually all studies
nvestigating open surgical techniques, we believe that for endovascu-
ar therapies, especially using stents, a distinction between these two
rteries should be made. They have very different anatomical proper-
ies. Where the CIA is a straight and immobile vessel, being fixed to
he sacral promontory, the EIA has a much more tortuous course,
long with stretching during extension of the hip.2 We believe these
roperties make the CIA more amenable to stenting with balloon-
xpandable stents, whereas in the EIA, self-expandable stents would
eem more appropriate. To our knowledge, no comparative studies
ave been published on this topic, but biomechanical studies do
onfirm our opinion.3 Furthermore, a retrospective study showed a
ecreased patency rate after stent placement in the EIA compared
ith a similar treatment in the CIA.4
In the Covered Versus Balloon Expandable Stent (COBEST)-
rial, subgroups were created based on the TransAtlantic Inter-
ociety Consensus (TASC) II classification. The TASC II guide-
ines classify lesions based on the amenability for endovascular
epair. Despite it being published only 4 years ago, more and more
apers are being published questioning the recommendations. The
ecommendation to avoid endovascular surgery in TASC C and D
esions is especially widely questioned.5 The TASC II classification
s rather generic, which makes it suitable for daily practice but less
or research purposes. For example, a TASC D lesion can range
rom aortoiliac occlusion to unilateral CIA, EIA, and common
emoral artery stenoses to bilateral EIA occlusions. When investi-
ating an intervention at a specific location, this classification seems
imited. In our opinion, it would be better to classify lesions based
n their anatomic characteristics, such as degree of stenosis or
cclusion, length, involvement of origin, and degree of calcifica-
ion, which is also advised by the DEFINE-group.6
If the authors could provide information about the performance
f the stents in the CIA and EIA and in different types of lesions, this
ould result in recommendations for tailor-made endovascular ther-
py.
In conclusion, we believe that in trials investigating stents in the
liac artery, a distinction must be made between the CIA and the EIA,
nd that subgroups should be created based on anatomic characteris-
ics of the investigated lesion, rather than the TASC II classification.
oost Anton Bekken, MD
ram Fioole, MD, PhD
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